Long Position on ARWR @ $33.00 on 9/4/2019 (Momentum)

Arrowhead Pharmaceuticals, Inc. (ARWR) develops medicines for the treatment of intractable diseases in the United States. 

The company is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target.ny's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. 

On August 5th, Arrowhead Pharma (ARWR) reported 3rd Quarter June 2019 earnings of $0.21 per share on revenue of $42.7 million. The consensus earnings estimate was $0.34 per share on revenue of $59.1 million.  Revenue grew 5,773.0% on a year-over-year basis. Since then shares are heading higher in an upward "trading channel" and are expected to move higher

Entry Point: $33.00

Stop Loss: $31.50

Trading Range: $10.41 - $36.80

Target Price: $36.30

Updates

10/17/2019 10:26:55 AM

ARWR closed at $35.50

Position closed on 10/17/2019 at price of $35.50 with a 7.58% gain in 43 days.

Back to Portfolio